OPSUMIT
Pronunciation: ma-si-TEN-tan (OP-sum-it)

What it isEndothelin receptor antagonist; pulmonary arterial hypertension.
Why this oneCompared with bosentan, it penetrates tissue better and does not require routine monthly liver testing.
What limits itEmbryo-fetal toxicity requires restricted dispensing and pregnancy prevention. Anemia and peripheral edema can limit use.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Pulmonary arterial hypertension (PAH) | Adults | 10 mg QD | 10 mg QD | 10 mg QD |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Contraindicated; teratogenic in animals at all doses; may cause fetal harm.
Lactation Advise not to breastfeed; no human data.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 10 mg | tab | 30 qd | offered |
Generic entry2021
⚠ BOXED WARNING
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.